IN8bio (NASDAQ:INAB) Price Target Lowered to $6.00 at HC Wainwright

IN8bio (NASDAQ:INAB) had its price target cut by HC Wainwright from $8.00 to $6.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

IN8bio Stock Performance

Shares of INAB opened at $0.23 on Friday. IN8bio has a 1 year low of $0.21 and a 1 year high of $1.74. The company has a market cap of $18.32 million, a price-to-earnings ratio of -0.30 and a beta of 0.03. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a fifty day moving average of $0.28 and a 200-day moving average of $0.30.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. As a group, equities analysts anticipate that IN8bio will post -0.56 earnings per share for the current year.

Hedge Funds Weigh In On IN8bio

Several hedge funds and other institutional investors have recently modified their holdings of INAB. BIOS Capital Management LP acquired a new position in shares of IN8bio during the fourth quarter valued at $2,212,000. Franklin Resources Inc. acquired a new stake in IN8bio in the fourth quarter worth about $1,465,000. Alyeska Investment Group L.P. lifted its holdings in IN8bio by 1,064.5% in the fourth quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock worth $1,302,000 after purchasing an additional 4,628,482 shares during the period. AIGH Capital Management LLC lifted its holdings in IN8bio by 269.7% in the fourth quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock worth $1,593,000 after purchasing an additional 4,517,227 shares during the period. Finally, Sigma Planning Corp lifted its holdings in IN8bio by 42.0% in the third quarter. Sigma Planning Corp now owns 851,280 shares of the company’s stock worth $230,000 after purchasing an additional 251,600 shares during the period. Institutional investors and hedge funds own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.